Pra Health Cmn Stk (PRAH) 55.48 $PRAH
Takeda and PRA Health Sciences Announce Transformational Clinical Development and Marketed Product Partnership
BusinessWire - Mon Sep 12, 8:00AM CDT
PRA Health Sciences, Inc. (NASDAQ: PRAH) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the companies have entered into a new partnership agreement under which PRA Health Sciences (PRA) will serve as Takeda's primary strategic partner to deliver on the company's pipeline and marketed products clinical development and post-approval needs.
PRAH: 55.48 (+0.73)
PRA Health Sciences (PRAH) Hits 52-Week High on Solid Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 7:59AM CDT
Share price of PRA Health Sciences (PRAH) rallied to a new 52-week high of $52.72 on Aug 23, eventually closing a tad bit higher at $52.59.
MASI: 59.85 (+0.54), PRAH: 55.48 (+0.73), CRY: 18.28 (+0.42), NUVA: 67.00 (+0.11)
PAREXEL International (PRXL) Q4 Earnings Beat, Up Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 8:12AM CDT
PAREXEL International (PRXL) reported fourth-quarter fiscal 2016 adjusted earnings per share of 94 cents.
PRXL: 69.20 (+0.76), ABCO: 44.31 (+1.32), HQY: 36.20 (+0.75), PRAH: 55.48 (+0.73)
PRA Health Sciences, Inc. Reports Second Quarter 2016 Results
GlobeNewswire - Thu Jul 28, 3:00PM CDT
-- $394.2 million of service revenue in the second quarter; 17.3% constant currency growth compared to the second quarter of 2015
PRAH: 55.48 (+0.73)
5 Medical Stocks with Incredibly Low PEG Ratios
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:08AM CDT
Medical is attractive for value investors due to its resiliency during volatile phases on the back of strong fundamentals of the constituent companies.
PMC: 26.67 (+0.16), ESRX: 69.65 (+0.40), AIRM: 31.90 (+0.06), PRAH: 55.48 (+0.73), MGLN: 53.91 (+0.61)
PRA Health Sciences (PRAH) Is in Oversold Territory: What's Next?
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:00AM CDT
PRA Health Sciences, Inc. (PRAH) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
PRAH: 55.48 (+0.73)
Why PRA Health Sciences (PRAH) Could Be an Impressive Growth Stock
Zacks Equity Research - Zacks Investment Research - Fri May 20, 7:44AM CDT
PRA Health Sciences (PRAH) has a favorable Zacks Rank and is a fast-growing stock that is well positioned for future earnings growth.
PRAH: 55.48 (+0.73)
PRA Health Sciences Named International Clinical Research Company of the Year
Globe Newswire - Tue May 17, 3:00AM CDT
RALEIGH, N.C., May 17, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ
RAH) is pleased to announce that for the third consecutive year it was recognized as the Clinical Research Company of the Year. PRA received the award at the PharmaTimes International Clinical Researcher of the Year ceremony in London. This award follows PRA's recent recognition as Clinical Research Company of the Year in the PharmaTimes Americas competition where PRA captured six individual awards, including two gold (Experienced CRA and Strategic Partnership-PRA and CytRx).
PRAH: 55.48 (+0.73)
PRA Health Sciences, Inc. Announces Secondary Offering of 5,000,000 Shares of Common Stock
GlobeNewswire - Mon May 02, 3:55PM CDT
PRA Health Sciences, Inc. (the "Company"
(NASDAQRAH) today announced that certain of its stockholders (the "Selling Stockholders", intend to offer for sale in an underwritten secondary offering 5,000,000 shares of common stock of the Company pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission. The Selling Stockholders will receive all of the proceeds from this offering. No shares are being sold by the Company. The last reported sale price of the Company's common stock on May 2, 2016 was $48.90 per share. The offering is expected to close on May 6, 2016, subject to customary closing conditions.
PRAH: 55.48 (+0.73), WFC: 45.83 (-0.73)
Becton, Dickinson (BDX): Stock Set to Top Earnings in Q2?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 2:11PM CDT
Becton, Dickinson and Company (BDX) is expected to report second-quarter fiscal 2016 results on May 5.
BDX: 179.38 (+3.49), CRDC: 2.35 (-0.15), ADAP: 7.23 (+0.15), PRAH: 55.48 (+0.73)
Can Weight Watchers (WTW) Pull a Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:15AM CDT
Weight Watchers International Inc. (WTW) is scheduled to release first-quarter 2016 results on May 4.
CRDC: 2.35 (-0.15), ADAP: 7.23 (+0.15), PRAH: 55.48 (+0.73), WTW: 10.48 (+0.36)
PRA Health Sciences reports 1Q loss
Automated Insights - Wed Apr 27, 4:31PM CDT
RALEIGH, N.C. (AP) _ PRA Health Sciences Inc. (PRAH) on Wednesday reported a first-quarter loss of $16 million, after reporting a profit in the same period a year earlier.
PRAH: 55.48 (+0.73)
PRA Health Sciences, Inc. Reports First Quarter 2016 Results and Updates 2016 Guidance
GlobeNewswire - Wed Apr 27, 3:00PM CDT
-- $372.3 million of service revenue in the first quarter; 13.0% constant currency growth compared to the first quarter of 2015
PRAH: 55.48 (+0.73)
CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the Strategic Partnership Team of the Year
PR Newswire - Mon Apr 25, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that two members of its clinical development team, Scott Wieland, Ph.D., Senior Vice President, Drug Development, and Nancy Wu, Senior Director of Clinical Operations, received the prestigious gold award at the PharmaTimes Clinical Researcher of the Year - The Americas competition held in Atlanta, Georgia. The award in the Strategic Partnership Team category is shared with CytRx's partners at PRA Health Sciences, Inc., (PRA) (Nasdaq: PRAH), which was also recognized at the competition as the Best Clinical Research Company of the Year for the second consecutive year.
CYTR: 0.59 (unch), PRAH: 55.48 (+0.73)
PRA Health Sciences Named Clinical Research Company of the Year
GlobeNewswire - Mon Apr 18, 11:20AM CDT
PRA Health Sciences, Inc., (PRA) (NASDAQRAH) is pleased to announce it was once again recognized as the Best Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Atlanta, Georgia. This is the second year in a row that PRA has received this prestigious recognition. In 2015 PRA was also named the Best International Clinical Company of the Year.
PRAH: 55.48 (+0.73)
PRA Health Sciences to Report First Quarter 2016 Earnings
GlobeNewswire - Fri Apr 15, 2:25PM CDT
PRA Health Sciences, Inc. (NASDAQRAH) will release its first quarter 2016 results after the market closes on Wednesday, April 27, 2016. The Company will also host a conference call on Thursday, April 28, 2016 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
PRAH: 55.48 (+0.73)
PAREXEL (PRXL): A Strong Buy on Solid Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 11:10AM CDT
On Apr 12, Zacks Investment Research raised PAREXEL International Corporation (PRXL) to a Zacks Rank #1 (Strong Buy).
PRXL: 69.20 (+0.76), LMAT: 21.62 (-0.16), PRAH: 55.48 (+0.73), OFIX: 43.58 (-0.59)
Is PRA Health Sciences (PRAH) a Great Growth Stock?
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 8:18AM CDT
PRA Health Sciences, (PRAH) looks like an exciting pick for investors as it is poised for strong future growth.
PRAH: 55.48 (+0.73)
PRA Health Sciences is Now Oversold (PRAH)
MarketNewsVideo.com - Mon Feb 08, 12:10PM CST
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
PRAH: 55.48 (+0.73)
Takeda and PRA Health Sciences Announce Transformational Clinical Development and Marketed Product Partnership
BusinessWire - Mon Sep 12, 8:00AM CDT
PRA Health Sciences, Inc. (NASDAQ: PRAH) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the companies have entered into a new partnership agreement under which PRA Health Sciences (PRA) will serve as Takeda's primary strategic partner to deliver on the company's pipeline and marketed products clinical development and post-approval needs.
PRAH: 55.48 (+0.73)
PRA Health Sciences (PRAH) Hits 52-Week High on Solid Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 24, 7:59AM CDT
Share price of PRA Health Sciences (PRAH) rallied to a new 52-week high of $52.72 on Aug 23, eventually closing a tad bit higher at $52.59.
MASI: 59.85 (+0.54), PRAH: 55.48 (+0.73), CRY: 18.28 (+0.42), NUVA: 67.00 (+0.11)
PAREXEL International (PRXL) Q4 Earnings Beat, Up Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 8:12AM CDT
PAREXEL International (PRXL) reported fourth-quarter fiscal 2016 adjusted earnings per share of 94 cents.
PRXL: 69.20 (+0.76), ABCO: 44.31 (+1.32), HQY: 36.20 (+0.75), PRAH: 55.48 (+0.73)
PRA Health Sciences, Inc. Reports Second Quarter 2016 Results
GlobeNewswire - Thu Jul 28, 3:00PM CDT
-- $394.2 million of service revenue in the second quarter; 17.3% constant currency growth compared to the second quarter of 2015
PRAH: 55.48 (+0.73)
5 Medical Stocks with Incredibly Low PEG Ratios
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:08AM CDT
Medical is attractive for value investors due to its resiliency during volatile phases on the back of strong fundamentals of the constituent companies.
PMC: 26.67 (+0.16), ESRX: 69.65 (+0.40), AIRM: 31.90 (+0.06), PRAH: 55.48 (+0.73), MGLN: 53.91 (+0.61)
PRA Health Sciences (PRAH) Is in Oversold Territory: What's Next?
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:00AM CDT
PRA Health Sciences, Inc. (PRAH) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
PRAH: 55.48 (+0.73)
Why PRA Health Sciences (PRAH) Could Be an Impressive Growth Stock
Zacks Equity Research - Zacks Investment Research - Fri May 20, 7:44AM CDT
PRA Health Sciences (PRAH) has a favorable Zacks Rank and is a fast-growing stock that is well positioned for future earnings growth.
PRAH: 55.48 (+0.73)
PRA Health Sciences Named International Clinical Research Company of the Year
Globe Newswire - Tue May 17, 3:00AM CDT
RALEIGH, N.C., May 17, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ
RAH) is pleased to announce that for the third consecutive year it was recognized as the Clinical Research Company of the Year. PRA received the award at the PharmaTimes International Clinical Researcher of the Year ceremony in London. This award follows PRA's recent recognition as Clinical Research Company of the Year in the PharmaTimes Americas competition where PRA captured six individual awards, including two gold (Experienced CRA and Strategic Partnership-PRA and CytRx). PRAH: 55.48 (+0.73)
PRA Health Sciences, Inc. Announces Secondary Offering of 5,000,000 Shares of Common Stock
GlobeNewswire - Mon May 02, 3:55PM CDT
PRA Health Sciences, Inc. (the "Company"
(NASDAQRAH) today announced that certain of its stockholders (the "Selling Stockholders", intend to offer for sale in an underwritten secondary offering 5,000,000 shares of common stock of the Company pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission. The Selling Stockholders will receive all of the proceeds from this offering. No shares are being sold by the Company. The last reported sale price of the Company's common stock on May 2, 2016 was $48.90 per share. The offering is expected to close on May 6, 2016, subject to customary closing conditions. PRAH: 55.48 (+0.73), WFC: 45.83 (-0.73)
Becton, Dickinson (BDX): Stock Set to Top Earnings in Q2?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 2:11PM CDT
Becton, Dickinson and Company (BDX) is expected to report second-quarter fiscal 2016 results on May 5.
BDX: 179.38 (+3.49), CRDC: 2.35 (-0.15), ADAP: 7.23 (+0.15), PRAH: 55.48 (+0.73)
Can Weight Watchers (WTW) Pull a Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:15AM CDT
Weight Watchers International Inc. (WTW) is scheduled to release first-quarter 2016 results on May 4.
CRDC: 2.35 (-0.15), ADAP: 7.23 (+0.15), PRAH: 55.48 (+0.73), WTW: 10.48 (+0.36)
PRA Health Sciences reports 1Q loss
Automated Insights - Wed Apr 27, 4:31PM CDT
RALEIGH, N.C. (AP) _ PRA Health Sciences Inc. (PRAH) on Wednesday reported a first-quarter loss of $16 million, after reporting a profit in the same period a year earlier.
PRAH: 55.48 (+0.73)
PRA Health Sciences, Inc. Reports First Quarter 2016 Results and Updates 2016 Guidance
GlobeNewswire - Wed Apr 27, 3:00PM CDT
-- $372.3 million of service revenue in the first quarter; 13.0% constant currency growth compared to the first quarter of 2015
PRAH: 55.48 (+0.73)
CytRx and PRA Health Sciences Receive Gold Awards for Excellence in Clinical Research as the Strategic Partnership Team of the Year
PR Newswire - Mon Apr 25, 8:00AM CDT
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that two members of its clinical development team, Scott Wieland, Ph.D., Senior Vice President, Drug Development, and Nancy Wu, Senior Director of Clinical Operations, received the prestigious gold award at the PharmaTimes Clinical Researcher of the Year - The Americas competition held in Atlanta, Georgia. The award in the Strategic Partnership Team category is shared with CytRx's partners at PRA Health Sciences, Inc., (PRA) (Nasdaq: PRAH), which was also recognized at the competition as the Best Clinical Research Company of the Year for the second consecutive year.
CYTR: 0.59 (unch), PRAH: 55.48 (+0.73)
PRA Health Sciences Named Clinical Research Company of the Year
GlobeNewswire - Mon Apr 18, 11:20AM CDT
PRA Health Sciences, Inc., (PRA) (NASDAQ
RAH) is pleased to announce it was once again recognized as the Best Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Atlanta, Georgia. This is the second year in a row that PRA has received this prestigious recognition. In 2015 PRA was also named the Best International Clinical Company of the Year. PRAH: 55.48 (+0.73)
PRA Health Sciences to Report First Quarter 2016 Earnings
GlobeNewswire - Fri Apr 15, 2:25PM CDT
PRA Health Sciences, Inc. (NASDAQ
RAH) will release its first quarter 2016 results after the market closes on Wednesday, April 27, 2016. The Company will also host a conference call on Thursday, April 28, 2016 at 9:00 a.m. (ET) to discuss the results with members of the investment community. PRAH: 55.48 (+0.73)
PAREXEL (PRXL): A Strong Buy on Solid Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 11:10AM CDT
On Apr 12, Zacks Investment Research raised PAREXEL International Corporation (PRXL) to a Zacks Rank #1 (Strong Buy).
PRXL: 69.20 (+0.76), LMAT: 21.62 (-0.16), PRAH: 55.48 (+0.73), OFIX: 43.58 (-0.59)
Is PRA Health Sciences (PRAH) a Great Growth Stock?
Zacks Equity Research - Zacks Investment Research - Tue Apr 12, 8:18AM CDT
PRA Health Sciences, (PRAH) looks like an exciting pick for investors as it is poised for strong future growth.
PRAH: 55.48 (+0.73)
PRA Health Sciences is Now Oversold (PRAH)
MarketNewsVideo.com - Mon Feb 08, 12:10PM CST
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
PRAH: 55.48 (+0.73)
